Systemic chemotherapy with pemetrexed and cisplatin for malignant peritoneal mesothelioma: A single institution experience

Citation:

Lainakis G, Zagouri F, Kastritis E, Sergentanis TN, Bozas G, Dimopoulos MA, Papadimitriou CA. Systemic chemotherapy with pemetrexed and cisplatin for malignant peritoneal mesothelioma: A single institution experience. Tumori [Internet]. 2011;97(1):25 - 29.

Abstract:

Background and aims. Primary malignant peritoneal mesothelioma is a rare malignancy with an unfavorable prognosis. Pemetrexed has proven effective in the treatment of malignant mesothelioma, alone or in combination with platinum agents. In the present study, chemo-naïve patients were evaluated for the efficacy and safety of the pemetrexed-cisplatin combination. Methods. Six patients with diffuse peritoneal mesothelioma were treated with 6 cycles of pemetrexed (500 mg/m2) and cisplatin (75 mg/m2). Chemotherapy was administered on an outpatient basis every 3 weeks. Results. Complete response was observed in 2 patients (33%) and partial response was observed in 3 patients (50%). The estimated median overall survival was 24 months and the estimated median time to disease progression was 9.5 months. The regimen was well tolerated. Conclusions. Though our data reflect a small sample size, pemetrexed plus cisplatin accomplished a particularly high clinical benefit rate on chemo-naïve patients. Free full text available at www.tumorionline.it.

Notes:

Cited By :11Export Date: 21 February 2017

Website